Last updated on June 2018

A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients


Brief description of study

This study is to evaluate efficacy and safety of Imatinib in two groups of patients; all patients should be diagnosed less than 3 months as chronic myeloid leukemia in a chronic phase. The group A, the reference group, will have 10% or less than 10% of the BCR-ABL level after three month dosing and be maintained their dose of 400mg/day. On the other hand, the group B, will have more than 10% and the dose will be increased from 400mg/day to 600mg/day. The superiority of the group B will be proved by evaluating the MMR rate of these two groups after 12 months of administeration of Imatinib.

Clinical Study Identifier: NCT02204722

Contact Investigators or Research Sites near you

Start Over

Kyu-hyung Lee, M.D.

Asan Medical Center
Seoul, Korea, Republic of